Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 238,768,883 papers from all fields of science
Search
Sign In
Create Free Account
olaparib
Known as:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
A substance being studied in the treatment of breast, ovarian, and prostate cancers caused by mutations (changes) in the BRCA1 and BRCA2 genes. It is…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
12 relations
Narrower (3)
AZD 2281
Lynparza
PARP Inhibitor AZD2281
Broader (4)
Antineoplastic Agents
Phthalazines
Piperazines
Poly(ADP-ribose) Polymerase Inhibitors
NCIt Antineoplastic Agent Terminology
PARP1 protein, human
Poly(ADP-Ribose) Polymerase Inhibitors [MoA]
olaparib 50 MG Oral Capsule
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Maintenance Olaparib New Standard in Pancreatic Cancer?
Cancer Discovery
2019
Corpus ID: 174813571
In a phase III trial, olaparib maintenance therapy significantly extended progression-free survival and duration of response in…
Expand
Review
2019
Review
2019
Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
R. McQueen
,
M. Whittington
,
R. Chapman
,
Varun M. Kumar
,
Jonathan D. Campbell
PharmacoEconomics (Auckland)
2019
Corpus ID: 141511740
In the March 2019 issue of Pharmacoeconomics, Guy et al. evaluated the cost effectiveness of niraparib compared with routine…
Expand
Review
2019
Review
2019
Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated.
N. Saleh
,
M. Copur
Oncology
2019
Corpus ID: 199056047
The US Food and Drug Administration recently approved a new indication for olaparib for maintenance treatment in adult patients…
Expand
2018
2018
Complete pathological remission after treatment with olaparib in apatient with PTEN-deficient sarcomatoid prostate cancer
Jue Wang
2018
Corpus ID: 86827214
Precision oncology utilizes the individual tumor genomic information to guide the optimal cancer treatment. In this case report…
Expand
2017
2017
Olaparib Keeps Hereditary Breast Tumors in Check.
Cancer Discovery
2017
Corpus ID: 7045046
In the phase III OlympiAD study, tumors shrank in about 60% of women with BRCA mutation-associated metastatic breast cancer who…
Expand
2017
2017
FDA approvals for the first 6 months of 2017
Asher Mullard
Nature reviews. Drug discovery
2017
Corpus ID: 20063192
2015
2015
Abstract 1653: BGB-290: A highly potent and specific PARP1/2 inhibitor potentiates anti-tumor activity of chemotherapeutics in patient biopsy derived SCLC models
Zhiyu Tang
,
Ye-Liu Liu
,
+19 authors
Lai Wang
2015
Corpus ID: 79466926
Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer with a 5-year survival rate of less than 10…
Expand
2015
2015
Olaparib effective in four advanced cancers.
Cancer Discovery
2015
Corpus ID: 35678328
In a phase II study, researchers found that the PARP inhibitor olaparib led to stable disease or tumor regressions in patients…
Expand
2014
2014
Association between the HER 2 Ile 655 Val polymorphism and response to trastuzumab in women with operable primary breast cancer
X. Han
,
L. Diao
,
+8 authors
Y. Xie
2014
Corpus ID: 2521353
1979; 35: 549–556. 19. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659–663. 20…
Expand
2011
2011
Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca).
Jung-Min Lee
,
C. Annunziata
,
+9 authors
E. C. Kohn
Journal of Clinical Oncology
2011
Corpus ID: 32165877
2520 Background: The PARPi O has single-agent activity against BRCA1/2 mutation carriers (Br/Ov mut+) Br/OvCa. We hypothesized…
Expand